Floatz logo

Apixaban

Intracranial Arteriosclerosis

Yonsei UniversitySmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Intracranial Arteriosclerosis cohort.

Asset / SponsorPhaseRating
Aspirin
Yonsei University
Phase 4BBB
Clopidogrel
Yonsei University
Phase 4BB
Rivaroxaban
University of Florida
Phase 3BB
Ticagrelor
University of Florida
Phase 3B
Urinary Kallikrein
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4B

View all 13 →

Same molecule, other indications

Apixaban is also rated in:

venous thromboembolismActive
BBB
Indicative · Phase 4
79 / 100
View asset →
atrial fibrillationActive
BBB
Indicative · Phase 4
77 / 100
View asset →
transient ischemic attackActive
BBB
Indicative · Phase 4
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →